Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 220 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolites Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Supplementation of Cholecalciferol and Related Active Metabolites Through Bioenhancing Layer's Eggs

NCT07859280
View directory record Official record
Conditions
Healthy Adult Participants, Vitamin D Insufficiency
Interventions
Vitamin D3 bioenhanced eggs, 25(OH)D3 bioenhanced eggs
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 24, 2026, 6:17 AM EDT
Terminated No phase listed Observational

Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19

NCT05044780
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants

NCT06727136
View directory record Official record
Conditions
Healthy Participants
Interventions
TBP-PI-HBr
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Results available

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

NCT02649608
View directory record Official record
Conditions
Parkinson Disease
Interventions
0.04 mg Lu AE04621, 0.08 mg Lu AE04621, 0.2 mg Lu AE04621, 0.4 mg Lu AE04621, 0.6 mg Lu AE04621, 0.8 mg Lu AE04621, 1.0 mg Lu AE04621, 1.2 mg Lu AE04621
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
45 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Hallandale, Florida • Orlando, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 24, 2026, 6:17 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy

NCT05169060
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
Fish Oil Concentrate, 1000 Mg Oral Capsule, Salsalate Oral Tablet
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Iowa City, Iowa • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women

NCT06259331
View directory record Official record
Conditions
Healthy Lactating Women
Interventions
SPN-812 (600mg, QD)
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 24, 2026, 6:17 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects

NCT01133873
View directory record Official record
Conditions
Healthy
Interventions
Propoxyphene napsylate (XP20C), Placebo
Drug
Lead sponsor
Xanodyne Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 24, 2026, 6:17 AM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

Acetaminophen Dosing in Obese Adolescents

NCT03192566
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Tylenol
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
10 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacotoxicology of Trichloroethylene Metabolites

NCT01128270
View directory record Official record
Conditions
Healthy
Interventions
Dichloroacetate environmental dose, Chloral Hydrate environmental dose, Dichloroacetate therapeutic dose, Chloral Hydrate therapeutic dose
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites

NCT01980329
View directory record Official record
Conditions
Cytochrome P450 CYP3A5 Enzyme Polymorphism, Healthy Subjects, Pharmacokinetics of Maraviroc
Interventions
Maraviroc
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 24, 2026, 6:17 AM EDT
Recruiting No phase listed Observational

Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression

NCT06017622
View directory record Official record
Conditions
Acute Cannabis-induced CNS Depression
Interventions
Not listed
Lead sponsor
Anebulo Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Worcester, Massachusetts • Cincinnati, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women

NCT00541931
View directory record Official record
Conditions
Skin Diseases
Interventions
Dietary Supplement: LifePak Nano
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 24, 2026, 6:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional and Metabolic Imaging Using Magnetic Resonance Imaging and Spectroscopy

NCT00001591
View directory record Official record
Conditions
Healthy, Nervous System Disease
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

NCT05140096
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Fluconazole, Isavuconazole
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood

NCT01899846
View directory record Official record
Conditions
Pregnancy
Interventions
Hydroxyprogesterone caproate 250 mg/ml
Drug
Lead sponsor
Lumara Health, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Lake Worth, Florida • Idaho Falls, Idaho • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 24, 2026, 6:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

NCT04006847
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Phase
Interventions
Eicosapentaenoic Acid, Tyrosine kinase inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 24, 2026, 6:17 AM EDT
Terminated Phase 2 Interventional Results available

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

NCT01978236
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
Dabrafenib 150 mg, Trametinib 2.0 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Folinic Acid in Autism

NCT03771560
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
folinic acid
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
5 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 24, 2026, 6:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites

NCT03665610
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 24, 2026, 6:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers for Cardiovascular Disease

NCT00109018
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tissue-Specific Metabolic Reprogramming in Diabetic Complications

NCT01823406
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Euglycemic clamp (normal blood sugar clamp) for 4 hours, hyperglycemic clamp (elevated blood sugar to 300) for 4 hours
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

NCT04991571
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 24, 2026, 6:17 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

NCT01406340
View directory record Official record
Conditions
Anaemia
Interventions
5 mg GSK1278863
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 24, 2026, 6:17 AM EDT
Completed Phase 2 Interventional

Role of Metabolites in Nicotine Dependence (3) - 6

NCT00000289
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Ondansetron
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 24, 2026, 6:17 AM EDT